TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04200898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheetah System
Description: For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
Study: NCT02653469

Intervention type: OTHER
Intervention: Augmented ventilation
Description: When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.

Intervention type: OTHER
Intervention: Fluid loading
Description: We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
Study: NCT02572986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin
Study: NCT04532333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin 250 MG Injection
Description: Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
Study: NCT00110084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
Description: 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
Study: NCT01396499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
Study: NCT01771081

Intervention type: DRUG
Intervention: Ranibizumab (or other DME treatment)
Description: Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
Study: NCT04049578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
Study: NCT02725840

Intervention type: RADIATION
Intervention: Proton beam radiation therapy.
Description: Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.

Intervention type: RADIATION
Intervention: X-ray based radiation therapy
Description: The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.

Intervention type: PROCEDURE
Intervention: Computed Tomography (CT) Scan
Description: Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months

Intervention type: PROCEDURE
Intervention: Computed Tomography (CT) Scan
Description: Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months

Intervention type: PROCEDURE
Intervention: Pulmonary Function Test (PFT)
Description: Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
Study: NCT02760238

Intervention type: OTHER
Intervention: Observational
Study: NCT02725840

Intervention type: PROCEDURE
Intervention: Pulmonary Function Test (PFT)
Description: Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
Study: NCT04526379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Evaluation of behavioral disorders of children with PWS by questionnaires

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Evaluation of behavioral disorders of children with PWS by questionnaires

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t-VNS
Description: Evaluation of the influence of 6 month-stimulation by t-VNS on emotional, cognitive, and behavioral/clinical characteristics of 12 children with PWS on 30 PWS patients included.
Study: NCT01555242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aneustat (OMN54)
Description: 100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
Study: NCT01874015

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mesenchymal cell transplantation
Description: Mesenchymal cell transplantation in patients with Crohn's disease.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mesenchymal cell and fibroblast injection
Description: Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
Study: NCT04559776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait analysis
Description: gait analysis with 3D optoelectronic system and surface EMG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait analysis
Description: gait analysis with 3D optoelectronic system and surface EMG
Study: NCT03952039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEDRATINIB
Description: A potent and selective inhibitor of JAK2 kinase activity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Best available therapy (BAT)
Study: NCT03047161

Intervention type: DEVICE
Intervention: fetal MCG
Description: assess fetal heart rate and rhythm

Intervention type: DEVICE
Intervention: fetal MCG
Description: assess fetal heart rate and rhythm
Study: NCT04219085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
Study: NCT04097067

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Low dose radiotherapy with 20 Gy (10x2Gy)
Study: NCT03691220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemetric Intervention
Description: Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
Study: NCT03609060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
Study: NCT03826329

Intervention type: OTHER
Intervention: observational study
Description: this is an observational study, there is no intervention in this study
Study: NCT04346615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant (BHV-3500)
Description: 10 mg intranasal (IN) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q8h for 14 days
Study: NCT01602276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS
Study: NCT00337649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epothilone D
Description: ≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epothilone D
Description: ≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 4mg/kg iv loading dose, followed by 2mg/kg iv weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 4mg/kg iv loading dose, followed by 2mg/kg iv weekly
Study: NCT01585896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Help Group
Description: The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, \& Steketee, 2007).
Study: NCT04498806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit device monitors daily activity as a measure of physical function.
Study: NCT03559972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-label facial injection
Description: Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-label facial injection
Description: Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection
Study: NCT02116270

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: 3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
Study: NCT04019977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Home Visiting Program
Description: Brief nurse home visiting program
Study: NCT03525561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide Pill
Description: Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
Study: NCT03035591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-207
Study: NCT00529373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: 50 mg tablet orally once weekly (OW)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Odanacatib
Description: 50 mg tablet orally OW

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5600 IU orally OW

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 5600 IU orally OW

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
Study: NCT03620201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study: NCT04991441

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Controlled Dietary Sodium Restriction
Description: Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Diet & Controlled Dietary Sodium Restriction
Description: Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
Study: NCT00881309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium
Description: TW 90mg/d
Study: NCT04537052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ven Restoration Therapy
Description: This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
Study: NCT00834288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: 1x200 mg Tramadol HCl OAD tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl
Description: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
Study: NCT04991441

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Diet & Controlled Dietary Sodium Restriction
Description: Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
Study: NCT04030299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-counter fitting
Description: In this group, pre-configured hearing aids, which simulate over-the-counter hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
Study: NCT02960724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-AE105 PET/CT
Description: One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
Study: NCT01228682

Intervention type: DRUG
Intervention: Tolvaptan
Description: Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
Study: NCT02252835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: 800 mg once daily orally for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: 40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: 600 mg once daily orally for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: 80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg daily
Study: NCT01935141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose IV Contrast
Description: A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Dose IV Contrast
Description: A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Siemens Sensation 64-MDCT scanner.
Description: The device will be used to perform CT Pulmonary Angiograms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Sensation 64-MDCT scanner.
Description: The device will be used to perform CT Pulmonary Angiograms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque 320 non-ionic isoosmolar contrast agent
Description: Single Dose of Intravenous Iodixanol will be administered per CT scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque 320 non-ionic isoosmolar contrast agent
Description: Single Dose of Intravenous Iodixanol will be administered per CT scan.
Study: NCT02912702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2000U/m2 day5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride liposome injection
Description: 25 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m2 was administered once on the first day of every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 150 mg/m2 twice weekly for 2 weeks and then weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
Study: NCT00594867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen - 4 grams per day + Placebo
Description: Acetaminophen - 4 grams per day + Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin - 325 mg per day + Placebo
Description: Aspirin - 325 mg per day + Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 gram per day + Aspirin 325 mg per day
Description: Acetaminophen 4 gram per day + Aspirin 325 mg per day
Study: NCT03472014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose
Study: NCT03711188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-101
Description: A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
Study: NCT02287181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: short acting opiate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: short acting opiate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: hypnotic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: hypnotic drug

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: electroencephalograph

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: electroencephalograph
Study: NCT03971032

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysteroscopy
Description: Diagnostic procedure
Study: NCT01241448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered Orally
Study: NCT00938431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
Study: NCT02734485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active Deep TMS
Description: The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Deep TMS
Description: The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
Study: NCT02764749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cranberry (poly)phenol containing supplement
Description: Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: cranberry (poly)phenol deprived supplement
Description: Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water